Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience

Menasché, Philippe, Vanneaux, Valérie, Fabreguettes, Jean-Roch, Bel, Alain, Tosca, Lucie, Garcia, Sylvie, Bellamy, Valérie, Farouz, Yohan, Pouly, Julia, Damour, Odile, Périer, Marie-Cécile, Desnos, Michel, Hagège, Albert, Agbulut, Onnik, Bruneval, Patrick, Tachdjian, Gérard, Trouvin, Jean-Hugues, Larghero, Jérôme·2015·European Heart Journal

Abstract

AIM: There is now compelling evidence that cells committed to a cardiac lineage are most effective for improving the function of infarcted hearts. This has been confirmed by our pre-clinical studies entailing transplantation of human embryonic stem cell (hESC)-derived cardiac progenitors in rat and non-human primate models of myocardial infarction. These data have paved the way for a translational programme aimed at a phase I clinical trial. METHODS AND RESULTS: The main steps of this programme have included (i) the expansion of a clone of pluripotent hESC to generate a master cell bank under good manufacturing practice conditions (GMP); (ii) a growth factor-induced cardiac specification; (iii) the purification of committed cells by immunomagnetic sorting to yield a stage-specific embryonic antigen (SSEA)-1-positive cell population strongly expressing the early cardiac transcription factor Isl-1; (iv) the incorporation of these cells into a fibrin scaffold; (v) a safety assessment focused on the loss of teratoma-forming cells by in vitro (transcriptomics) and in vivo (cell injections in immunodeficient mice) measurements; (vi) an extensive cytogenetic and viral testing; and (vii) the characterization of the final cell product and its release criteria. The data collected throughout this process have led to approval by the French regulatory authorities for a first-in-man clinical trial of transplantation of these SSEA-1(+) progenitors in patients with severely impaired cardiac function. CONCLUSION: Although several facets of this manufacturing process still need to be improved, these data may yet provide a useful platform for the production of hESC-derived cardiac progenitor cells under safe and cost-effective GMP conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu192

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 177

Metadata

Authors
Menasché, P., Vanneaux, V., Fabreguettes, J.-R., Bel, A., Tosca, L., Garcia, S., Bellamy, V., Farouz, Y., Pouly, J., Damour, O., Périer, M.-C., Desnos, M., Hagège, A., Agbulut, O., Bruneval, P., Tachdjian, G., Trouvin, J.-H., & Larghero, J.
Venue
European Heart Journal
Published
2014-05-16
Volume
36
Issue
12
Pages
743-750
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2096559217
Cited by
177
References
1
FWCI
9.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. https://app.cochat.ai/papers/10.1093/eurheartj/ehu192
The paper
Menasché, P., Vanneaux, V., Fabreguettes, J.-R., Bel, A., Tosca, L., Garcia, S., Bellamy, V., Farouz, Y., Pouly, J., Damour, O., Périer, M.-C., Desnos, M., Hagège, A., Agbulut, O., Bruneval, P., Tachdjian, G., Trouvin, J.-H., & Larghero, J. (2015). Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu192

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.